Trial Profile
Efficacy of nilotinib or dasatinib in patients with chronic myeloid leukemia who are resistant to imatinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 13 May 2016 New trial record